Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy
NCT05655195
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. The investigator's lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only reduced amyloid and tau in the brain, but also improved memory. The investigators developed a light and sound device for humans that stimulates the brain at 40Hz that can be used safely at home.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Alzheimer Disease
- Alzheimer Disease, Early Onset
- Alzheimer Disease, Late Onset
- Alzheimer's Disease (Incl Subtypes)
- Alzheimer's
- Alzheimer's Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 65 to 100 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Massachusetts Institute of Technology
- Last updated on ClinicalTrials.gov
- March 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Massachusetts Institute of Technology · Cambridge, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.